Jan Bubenik
Overview
Explore the profile of Jan Bubenik including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
268
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sedlmajer M, Zach J, Bubenik J, Bydzovsky J, Novak V
Polymers (Basel)
. 2024 Nov;
16(22).
PMID: 39599236
This article addresses the potential use of secondary polymer fibres in the field of structural concrete as a replacement for primary polymer fibres (mainly polypropylene/PP/), which are used in concrete...
2.
Simova J, Sapega O, Imrichova T, Stepanek I, Kyjacova L, Mikyskova R, et al.
Oncotarget
. 2016 Jul;
7(34):54952-54964.
PMID: 27448982
Standard-of-care chemo- or radio-therapy can induce, besides tumor cell death, also tumor cell senescence. While senescence is considered to be a principal barrier against tumorigenesis, senescent cells can survive in...
3.
Rosalia R, Stepanek I, Pollakova V, Simova J, Bieblova J, Indrova M, et al.
Immunobiology
. 2012 Nov;
218(6):851-9.
PMID: 23182710
CD4(+)CD25(+)Foxp3(+) T regulatory cells (Tregs) and CD1d-restricted invariant natural killer T (iNKT) cells are two cell types that are known to regulate immune reactions. Depletion or inactivation of Tregs using...
4.
Mikyskova R, Indrova M, Simova J, Bieblova J, Bubenik J, Reinis M
Oncol Rep
. 2011 Mar;
25(6):1683-9.
PMID: 21424130
Genetically modified tumour cells producing cytokines such as interleukin 12 (IL-12) are potent activators of the antitumour immune responses and represent a promising therapeutic modality when combined with chemotherapy. The...
5.
Indrova M, Simova J, Bieblova J, Bubenik J, Reinis M
Oncol Rep
. 2010 Nov;
25(1):281-8.
PMID: 21109988
Loss or downregulation of MHC class I molecules on tumour cells is a common mechanism by which tumours can escape T-cell mediated immune responses. In this study, we examined the...
6.
Reinis M, Stepanek I, Simova J, Bieblova J, Pribylova H, Indrova M, et al.
Int J Oncol
. 2010 Feb;
36(3):545-51.
PMID: 20126973
Downregulation of MHC class I expression on the cell surface is a common mechanism by which tumour cells, including cervical carcinoma, can escape the T cell-mediated anti-tumour immunity. This downregulation...
7.
Simova J, Indrova M, Bieblova J, Mikyskova R, Bubenik J, Reinis M
Int J Cancer
. 2009 Sep;
126(12):2997-3004.
PMID: 19739073
Natural killer T (NKT) cells are potent modulators of antitumor immunity. Their protective effects can be achieved upon their activation by glycolipid ligands presented in the context of the CD1d...
8.
Indrova M, Bieblova J, Rossowska J, Kuropka P, Pajtasz-Piasecka E, Bubenik J, et al.
Int J Oncol
. 2008 Dec;
34(1):173-9.
PMID: 19082488
We have examined the effect of IL-12-producing cellular vaccines on the cytotoxicity and proliferative potential of CD45+ tumour-infiltrating cells (TIL) in mice carrying syngeneic TC-1 and TC-1/A9 HPV 16-associated tumours...
9.
Indrova M, Bieblova J, Bubenik J, Reinis M
Int J Oncol
. 2008 Jan;
32(2):499-507.
PMID: 18202774
We have established animal models of HPV16-associated tumours with distinct levels of MHC class I expression. This model was used for examination of immune responses, production of cytokines and kinetics...
10.
Manning J, Indrova M, Lubyova B, Pribylova H, Bieblova J, Hejnar J, et al.
Immunology
. 2007 Aug;
123(2):218-27.
PMID: 17725605
Epigenetic events play an important role in tumour progression and also contribute to escape of the tumour from immune surveillance. In this study, we investigated the up-regulation of major histocompatibility...